Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “PLASMACYTOMA”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 703 records · Page 39Linked to original sources
PubMedDate not supplied

Solitary plasmacytoma of the chest wall. A case report.

Solitary plasmacytic lymphomas are rarely described in the lung. Generally, localized neoplasms develop into mediastinal or pulmonary lymphnodes and are hard to differentiate from other lung neoplasms. An involvement of the chest wall in multiple myeloma is not rare, and is generally associated with other skeletal localizations. A secreting solitary plasmacytoma of the ribs is rather uncommon: a personal review of the literature has showed, in the last ten years, only two cases of these tumors, secreting IgG lambda light chains. In this study we report a case of solitary plasmacytoma of the chest wall, associated with an IgG kappa monoclonal gammapathy.

Aged↗
PubMed1989

[An autopsy case of primary cutaneous plasmacytoma].

An autopsy case of primary cutaneous plasmacytoma with very unusual extensive skin involvement resulting in death 9 months later, was reported. A 75-year-old female was admitted to our hospital in November, 1985 because of an enlarging skin nodule on the right neck of 5 month's duration. The nodule was a 5 x 7 x 4-cm, firm and mobile mass. Light- and electron-microscopic studies of its biopsy specimen revealed a cutaneous plasmacytoma which was composed of dense aggregates of plasma cells. Cytogenic study on the biopsy specimen revealed hypotetraploid and structural abnormalities such as 7q+, 11q+ and 20q+. After radiotherapy, the right neck nodule became smaller, but subcutaneous indurations with erosions extended to the surrounding skin. The biopsy specimen of these skin lesions microscopically revealed massive infiltrations of plasma cells in the dermis. The PAP method revealed a definite evidence of monoclonal kappa light chain production by these cells. 3H-thymidine were incorporated in 5.6% of the plasma cells. The skin lesions were refractory to chemotherapy and gradually extended. The clinical course showed a progressive one leading to persistent deterioration and she died in August, 1986. Repeated examinations including immunoelectrophoresis of serum and concentrated urine, bone marrow aspirations and skeletal x-ray films, excluded the diagnosis of myeloma. At autopsy, massive infiltrations of plasma cells in the skin of chest wall and neck, small metastatic tumors in the liver and bilateral axillary lymph nodes were found, but there was no evidence of bone marrow involvement.

Aged↗
PubMedDate not supplied

Primary gastric lymphoplasmacytoid malignant lymphoma (gastric plasmacytoma): an endoscopic cytologic diagnosis.

A case of primary gastric plasmacytoma in which diagnosis was made preoperatively by an endoscopic technique is presented. Exfoliative cytology using a brush under direct visual control enabled the case to be classified as lymphoplasmacytoid malignant lymphoma. Data which favor the diagnosis of plasmacytoma are: 1) plasma cells in various stages of maturation, 2) abnormal plasma cells often in mitotic division, 3) the presence of atypical immunoblasts.

Adult↗
PubMedDate not supplied

[Breast plasmacytoma. Apropos of a case. Review of the literature].

The authors report a new case of a bilateral localisation of a mammary plasmacytoma, as an extension of the multiple myeloma, in a 41-year-old woman. There are 19 cases known. In 2/3 of the cases, the breast localisation was an extension of the multiple myeloma, as the new case reported; the others cases were considered as a solitary plasmacytoma. The authors describe its diagnostic imaging appearance.

Adult↗
PubMed1989

C-myc-S mu rearrangement in a murine plasmacytoma without visible chromosomal translocations.

We report here that one murine plasmacytoma (DCPC 21) arising in a Balb/c mouse implanted i.p. with a Millipore diffusion chamber lacks any known chromosomal translocations. In situ molecular hybridization analysis of the metaphase spreads of DCPC 21, however, revealed that the c-myc gene has moved to the IgH locus on the chromosome 12. Further, an Ig switch region-mediated recombination was detected. The DNA sequencing analysis demonstrated that the c-myc gene has juxtaposed directly to S mu 5'-flanking sequence in a 'head-to-tail' orientation. The results strongly support our notion that the c-myc rearrangement is an essential step in the genesis of murine plasmacytomas, whether or not they have visible chromosomal translocations.

Animals↗
PubMed1989

[Solitary plasmacytoma of the mandible].

Solitary plasmacytoma of the bone is believed to be manifestation of the spectrum of diseases presented by the term plasma cell neoplasms and the lesion rarely involves the jaws. A case of solitary plasmacytoma of the mandible is presented, the diagnostic problem is posed and the method of treatment by peripheral osteotomy and radiotherapy discussed.

Adult↗
PubMed1978

Therapy of the murine plasmacytoma MOPC 104E: role of the immune response.

The murine plasmacytoma MOPC 104E was susceptible to cytotoxic therapy in female inbred BALB/c mice. Palpable subcutaneous tumors (0.6--1.2 X 10(8) cells) could be cured with a single administration of cyclophosphamide (5--250 mg/kg) or localized irradiation (800--2,400 R). Clonogenic assay showed that, following minimal curative doses of cyclophosphamide or radiation, 0.5--1.5 X 10(6) tumor cells should remain viable. Control animals succumbed to progressive, invariably lethal tumor growth after they were given sc injections of 2--3 X 10(3) tumor cells. Minimal doses of cyclophosphamide, which were curative in control tumor-bearing animals, were ineffective in treating tumor-bearing animals immunosuppressed by 450 R whole-body irradiation. Subsequent experiments measured the ability of animals cured of the murine plasmacytoma to reject secondary challenge with the same tumor. These experiments demonstrated and partially quantitated the substantial role of the immune response in effecting tumor cure following radiotherapy or chemotherapy.

Animals↗
PubMed1985

Cellular changes and antitumor responses in the plasmacytoma-bearing mouse following cyclophosphamide treatment.

Mice bearing the immunosuppressive plasmacytoma TEPC-183 exhibit a marked splenic hyperplasia. We have characterized these tumor-reactive splenocytes on the basis of cell surface marker expression, nonspecific esterase activity, and morphology. Although splenocyte numbers increased progressively throughout tumor growth, B- and T-lymphocytes, as defined by surface immunoglobulin and Thy-1 antigen expression, respectively, did not increase significantly. Fourteen days after tumor implantation, T-lymphocytes decreased from 70 million to 50 million per spleen. However, cells expressing Mac-1 antigen or nonspecific esterase activity increased from 10 to 65 million. This constituted a 6-fold increase in splenic macrophages. Further studies utilizing the expression of PC.2 antigen in conjunction with morphological examination indicated that metastatic TEPC-183 cells comprise approximately 5% of the tumor-host splenocyte population 14 days after implantation. Ablation of plasmacytoma by cyclophosphamide inhibited the tumor-associated splenocytosis and led to an increase in splenic T-cells (from 70 to 120 million). In addition, macrophage numbers returned to normal. This study also assessed the ability of splenocytes from animals with either actively growing tumors or those from cyclophosphamide-treated tumor-bearing mice to mediate an antitumor response. Splenocytes, when assessed 1 wk following tumor ablation by cyclophosphamide, demonstrated antitumor activity in Winn neutralization assays. This activity was not detectable in splenocytes from animals with progressively growing tumors. Additional studies revealed that the cell population involved in the antitumor effect was glass nonadherent, nylon-wool nonadherent, and expressed Thy-1 antigen. These observations were consistent with the expansion of the splenic T-lymphocyte population following cyclophosphamide treatment. However, the immune response directed against primary TEPC-183 tumor cells was not inhibitory to metastatic tumor cells.

Animals↗
PubMed1987

[An autopsy case of plasmacytoma of the thyroid gland].

An autopsy case of a 75-year-old woman with plasmacytoma of the thyroid gland is presented. There were no toxic symptoms and no abnormal serum protein. On autopsy, a nodule measuring 5.5 X 4.5 X 8 cm was found in the left lobe of the thyroid gland. No myeloma lesions were found in the bone marrow or in other organs. Histologically, the marginal area of the nodule was occupied by typical plasmacytoma, whereas necrotic tissues resembling anaplastic carcinoma were present in the central portion. Chronic thyroiditis was not associated. Immunohistochemically, only the kappa-light chain was demonstrated in the cytoplasm of the tumor cells.

Aged↗
PubMed1988

[A case of plasmacytoma (IgD lambda) of the breast associated with multiple myeloma].

A case of secondary plasmacytoma (Ig. D. lambda) of the breast, associated with multiple myeloma, is reported, involving a 60-year-old woman in whom multiple tumors of the right breast appeared during the course of her treatment for multiple myeloma. These breast tumors were firm, non-tender, clear-margined, smooth-surfaced, and showed good mobility. An ultrasonogram revealed that the tumors had the shape of a clear-margined anechoic mass like a cyst. A histological diagnosis of a biopsied specimen determined plasmacytoma (Ig. D, lambda) and the patient was treated with chemotherapy which caused the tumors to greatly reduce.

Breast↗
PubMed1988

Alternative expression of secreted and membrane forms of immunoglobulin mu-chain is regulated by transcriptional termination in stable plasmacytoma transfectants.

During B cell differentiation the mu H chain of IgM is produced initially as a cell surface (m) and later as a secreted (s) form. Production of either the secreted (microseconds) or the membrane (micron) mRNA results from selection of either the promoter proximal (microseconds) or distal (micron) poly(A)/cleavage site. We have transfected lymphoid cell lines of disparate developmental stages with productively rearranged Ig mu-chain constructs to determine the mechanism by which alternative 3' end selection is achieved. Stable transfectants of lymphomas (early stage, microseconds less than or equal to micron) and a plasmacytoma (late stage, microsecond much greater than micron) produce the anticipated levels of microsecond and micron mRNA. Transcription termination between the microsecond and micron poly(A) sites occurs only in the plasmacytoma transfectants, and appears to be the rate-limiting step in the production of the final steady state microsecond/micron mRNA ratio. We propose that as the B cell becomes terminally committed to secretion, the mechanism responsible for the regulation of the steady state microsecond/micron mRNA ratio shifts from exclusively post-transcriptional to predominantly transcriptional termination.

Animals↗
PubMed1988

Lack of radiosensitization in Lewis lung carcinoma and a murine plasmacytoma by MTDQ and MTDQ-DA.

MTDQ, and its watersoluble derivative MTDQ-DA, have been tested in combination with radiation using the murine plasmacytoma X5563 and the Lewis lung carcinoma. Neither of the two compounds showed any effect on the single dose radiation response as measured by tumour growth delay. In addition no effect of MTDQ-DA on the response of the X5563 plasmacytoma to fractionated radiation was observed. As a control, studies with the established hypoxic cell sensitizer Misonidazole showed that both tumours could be sensitized to radiation by that drug, in the case of Lewis lung carcinoma the use of the excision cell survival assay showed that this was due to hypoxic cell sensitization.

Animals↗
PubMed1988

Effector mechanism of tumor immunity in murine plasmacytoma.

The development of concomitant tumor immunity to plasmacytoma (PC) was previously demonstrated by the detection of splenic immune T-lymphocytes that inhibited the growth of PC in local adoptive transfer (Winn) assay. This immunity was down-regulated by cyclophosphamide-sensitive suppressor T-cells. The effector mechanism was further studied. It was found that immune spleen cells contained no cytotoxic T-lymphocytes as determined by 51Cr release assay. Immune spleen cells, however, exerted a cytostatic effect on PC cells in vitro; coculture of immune spleen cells with PC cells inhibited the [3H]thymidine uptake by tumor cells. No in vitro generation of cytolytic activity was observed. The cytostatic effector cells were found to be radiosensitive, nonadherent, Thy-1+, Lyt-1-2+ lymphocytes that required direct cell-cell contact for cytostasis. Plasmacytoma arising from transplants of mixtures of PC cells and immune spleen cells had a slower growth rate in vivo and incorporated less [3H]thymidine in vitro, findings consistent with the cytostatic effect of immune spleen cells. Studies comparing cytostatic cells assayed in vitro and immune splenic effector cells assayed in vivo (Winn assay) revealed that the former were short-lived (less than 26 days), high dose cyclophosphamide (200 mg/kg) resistant, and cross-reacting to other PC, whereas the latter were long-lived (greater than or equal to 102 days), high dose cyclophosphamide sensitive, and individual tumor specific. Immune spleen cells, however, could inhibit heterologous PC growth in vivo, if the homologous PC were also present. These findings are consistent with the hypothesis that the concomitant tumor immunity in PC involves terminal cytostatic effector T-cells with a broader target spectrum and tumor-specific helper T-cells that are required for clonal expansion and maturation of cytostatic cells in vivo.

Animals↗
PubMed1987

Diagnosis and management of plasmacytomas.

Although no optimal dose-response relationship has been defined for the local control of extramedullary plasmacytomas, the author recommends high local doses of 5000 cGy or more and field sizes sufficient to cover the primary mass, all its extensions as evident by CT scan, and the regional lymph nodes. Plasmacytomas of bone also should be treated aggressively.

Bone Neoplasms↗
PubMed1988

Plasmacytoma of the parotid gland. Report of a case and review of the world literature.

Extramedullary plasmacytoma (EP) is a relatively rare neoplasm; about 90% of cases are localized in the head and neck area. EP has been considered a precursor of multiple myeloma but cases showing long disease free intervals or cure by surgery alone have been reported. A research of the world literature pointed out the extremely rare localization of solitary plasmacytoma in the salivary glands. Only 9 cases have been reported until now, 6 in the parotid gland, 2 in the submandibular glands and 1 in both the parotid and submandibular gland.

Humans↗
PubMed1988

[Plasmacytoma of the mediastinum. A new case].

We report the case of a 61-year old man in whom ablation of a hilar tumour enabled us to diagnose a mediastinal plasmacytoma. Plasmacytomas are rarely found in the mediastinum and sometimes evolve towards myelomas. The best treatment seems to be surgery combined with radiotherapy. The effectiveness of chemotherapy against this tumour is questionable.

Humans↗
PubMed1987

Plasmacytoma of the breast. An unusual case of recurrent myeloma.

An unusual case of multiple myeloma is presented in which recurrence of the disease after a four-year remission was heralded by an infiltrating plasmacytoma of the breast. The clinical and histologic features of this neoplasm are presented and compared with ten previously reported cases of plasmacytoma of the breast.

Breast Neoplasms↗
PubMed1986

[Solitary intracranial plasmacytoma--a case report and review of the literature].

A 49 year old man had had headache and some cranial nerve paralyses for about three years. A tentative diagnosis of meningioma of the skull base or chordoma was made before his death. In the postmortem examination, a large tumor lying on the skull base was found. The sella turcica, a part of the basilar bone were destroyed. The neoplasm had invaded the adjacent cerebrum, cranial nerves and extra-cranial tissues. Histopathologically, the lesion showed a typical poorly-differentiated plasmacytoma. Both clinic and pathologic characteristics of this tumor are discussed and the literature on solitary intracranial plasmacytoma is reviewed.

Brain Neoplasms↗